Guardant Health spotlights 25 ESMO 2026 abstracts as methylation-based ctDNA monitoring takes center stage
Market Chameleon (Wed, 21-Oct 11:20 AM)
Guardant Health Faces Over $245 Million Judgment and 6% Royalty on Key Products Following Patent Verdict
Market Chameleon (Mon, 24-Aug 8:51 AM)
Guardant Health Raises 2026 Revenue Guidance on 44% Q2 Growth and Major Clinical Milestones
Market Chameleon (Fri, 31-Jul 7:07 AM)
